Overview

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Status:
Completed

Trial end date:
2017-01-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of ASP1941 50mg once daily in combination with metformin and sitagliptin against placebo in combination with metformin and sitagliptin over a 24 week treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin and sitagliptin.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Korea, Inc.

Treatments:

Ipragliflozin
Metformin
Sitagliptin Phosphate